Co-Authors
This is a "connection" page, showing publications co-authored by DEBASISH TRIPATHY and RACHEL M. LAYMAN.
Connection Strength
1.047
-
Efficacy of Single-Agent Chemotherapy in Endocrine Therapy-Refractory Metastatic Invasive Lobular Carcinoma. Oncologist. 2024 Mar 04; 29(3):213-218.
Score: 0.244
-
Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer. 2023 09; 191:113250.
Score: 0.234
-
Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open. 2023 05 01; 6(5):e2313017.
Score: 0.230
-
Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022 Jun; 193(2):253-264.
Score: 0.214
-
Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
Score: 0.062
-
Maintenance Pembrolizumab Therapy in Patients with Metastatic HER2-negative Breast Cancer with Prior Response to Chemotherapy. Clin Cancer Res. 2024 Jun 03; 30(11):2424-2432.
Score: 0.062